|Articles|August 26, 2022
Choose Eurofins’ new state-of-the-art aseptic sterile fill/finish for clinical supplies
Author(s)Eurofins
Industry changes can often introduce additional risks to the sterile fill/finish process, resulting in production delays, additional costs, and safety concerns. Choose Eurofins BioPharma Product Testing to help eliminate associated risks.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
2
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
3
Industry Outlook 2026: Key Forces Transforming Drug Pipelines (Part 2)
4
Eli Lilly Announces New $3.5 Billion Manufacturing Facility in Pennsylvania
5